Cell Source Inc
Cell Source, Inc., a biotechnology company, engages in developing cell therapy treatments based on the management of immune tolerance. Its lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The company's Veto Cell technology is used in various applications, including treatment of ly… Read more
Cell Source Inc (CLCS) - Total Assets
Latest total assets as of September 2024: $264.66K USD
Based on the latest financial reports, Cell Source Inc (CLCS) holds total assets worth $264.66K USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cell Source Inc - Total Assets Trend (2012–2023)
This chart illustrates how Cell Source Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cell Source Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Cell Source Inc's total assets of $264.66K consist of 100.0% current assets and 0.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how Cell Source Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cell Source Inc's current assets represent 100.0% of total assets in 2023, unchanged from 100.0% in 2012.
- Cash Position: Cash and equivalents constituted 11.4% of total assets in 2023, down from 100.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Cell Source Inc Competitors by Total Assets
Key competitors of Cell Source Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cell Source Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cell Source Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cell Source Inc is currently not profitable relative to its asset base.
Cell Source Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.01 | 0.02 | 0.02 |
| Quick Ratio | 0.01 | 0.02 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-18.94 Million | $ -16.03 Million | $ -5.60 Million |
Cell Source Inc - Advanced Valuation Insights
This section examines the relationship between Cell Source Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 55.18 |
| Asset Growth Rate (YoY) | -52.4% |
| Total Assets | $195.17K |
| Market Capitalization | $10.77 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cell Source Inc's assets at a significant premium ( 55.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cell Source Inc's assets decreased by 52.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cell Source Inc (2012–2023)
The table below shows the annual total assets of Cell Source Inc from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $195.17K | -52.38% |
| 2022-12-31 | $409.85K | +30.62% |
| 2021-12-31 | $313.77K | -30.63% |
| 2020-12-31 | $452.34K | +294.08% |
| 2019-12-31 | $114.78K | -78.41% |
| 2018-12-31 | $531.68K | 0.00% |
| 2017-12-31 | $531.68K | +151.86% |
| 2016-12-31 | $211.10K | -42.60% |
| 2015-12-31 | $367.76K | +198.74% |
| 2014-12-31 | $123.11K | +559.41% |
| 2013-12-31 | $18.67K | -15.34% |
| 2012-12-31 | $22.05K | -- |